STAT3 and hepatocellular carcinoma: Published clinical trials have shown that antibiotic chemotherapeutics can promote the combination of STAT3 and PD-L1 to upregulate GSDMC mediated pyroptosis under hypoxia (Blasco and Gomis, 2020), which may improve HCC patient survival compared to patients received only a single type of treatment to improve the efficiency of PD-L1 inhibitors.